InspireMD Inc. buy stratec
Start price
10.01.18
/
50%
€5,512.5
Target price
10.01.19
€13,388
Performance (%)
-98.00%
End price
10.01.19
€110.25
Summary
This prediction ended on 10.01.19 with a price of €110.25. The BUY prediction by stratec for InspireMD Inc. performed very badly with a performance of -98.00%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| InspireMD Inc. | -2.041% | -2.041% | -56.757% | -25.581% |
| iShares Core DAX® | 0.224% | 1.805% | 3.203% | 50.396% |
| iShares Nasdaq 100 | 6.047% | 15.716% | 39.608% | 108.035% |
| iShares Nikkei 225® | 5.724% | 12.343% | 50.337% | 73.481% |
| iShares S&P 500 | 2.172% | 7.723% | 26.167% | 72.779% |
Comments by stratec for this prediction
In the thread InspireMD Inc. diskutieren
InspireMD expects Q4 2017 sales of ~$833K (+159%)
The company says the CGuard* stent is designed to prevent embolization (blocking a blood vessel) by
trapping potential emboli against the arterial wall while maintaining excellent blood flow.
* Das CGuardTM Embolic Prevention System (EPS) wurde entwickelt, um eine peri-prozedurale und späte Embolisation zu verhindern, indem mögliche Emboli gegen die Arterienwand abgefangen werden, während gleichzeitig eine ausgezeichnete Perfusion zu der äußeren Halsschlagader und den
Nebengefäßen aufrechterhalten wird.
(Laufzeit überschritten)